Laurie Fenton Ambrose

Name: Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum
Start: 2025-09-07T18:30:00+02:00
End: 2025-09-07T19:30:00+02:00

September 1, 2016

|

By

|

Estimated Read Time:

1 minute

Names & News

Laurie Fenton Ambrose received the 2016 James L. Mulshine, MD Leadership Award, which recognized her efforts in guiding patient advocacy and other stakeholder groups in the successful efforts to gain coverage of lung cancer screening by the Centers for Medicare & Medicaid Services (CMS). Ms. Ambrose is President and CEO of the Lung Cancer Alliance.

About the Authors

Share this Article:

Laurie Fenton Ambrose

Recent Posts

World Conference Conversations: Inside WCLC 2025

Opening Plenary to Highlight Significant Achievements in Thoracic Oncology

Third Annual Amazing Case Race Returns for WCLC 2025

Preconference Workshops Offer Diverse Educational Opportunities Across Specialties

IS03: Satellite EBAC/CME Symposium by Answers in CME: Reshaping the Management of Metastatic NSCLC: Tackling HER2 Overexpression to Elevate Outcomes

Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC